Integrin alpha4beta7 Inhibitors
3 drugsAbout Integrin alpha4beta7
Integrin alpha4beta7 (α4β7) is a cell surface receptor mediating leukocyte trafficking, especially to the gut, by binding to MAdCAM-1 on endothelial cells. This interaction facilitates immune cell adhesion and infiltration, driving inflammation in target tissues. α4β7 is thus a key player in immune responses.
α4β7 is a therapeutic target for modulating immune cell migration, though no genetic evidence directly links it to specific diseases. Blocking α4β7/MAdCAM-1 interaction reduces inflammation, making it relevant for autoimmune and inflammatory conditions.
Three FDA-approved drugs target α4β7: TYRUKO, ENTYVIO, and TYSABRI. These include antibody (2 drugs) and other biologic (1 drug) modalities, developed by Novartis, Takeda and Biogen, respectively, for CNS, immunology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Colitis with only 2 trials.
- Emerging modalities (Small molecule) signal innovation opportunity.
Top Integrin alpha4beta7 Drugs
The competitive landscape includes Novartis, Takeda, and Biogen, each with an approved drug.
High concentration of approved drugs among three companies suggests significant barriers to entry.
Integrin alpha4beta7 Drug Modality Landscape
Modalities
Routes of Administration
Integrin alpha4beta7 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Consider novel modalities to differentiate from existing antibody-based therapies and capture market share.
📈 Modality Evolution
Antibodies pioneered Integrin alpha4beta7 targeting (2004), with other biologics entering more recently (2023).
Integrin alpha4beta7 Clinical Trials 126 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 14 | 4 | 2 | 78% |
| Phase 2 | 28 | 14 | 6 | 8 | 70% |
| Phase 3 | 32 | 15 | 7 | 10 | 68% |
| Phase 4 | 46 | 23 | 12 | 11 | 66% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved Integrin alpha4beta7 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Integrin alpha4beta7. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Integrin alpha4beta7 Drug Approval Timeline (2004 - 2023)
The approval timeline spans 20 years, from TYSABRI (2004) to TYRUKO (2023).
The recent approval of TYRUKO indicates continued interest and potential in targeting Integrin alpha4beta7.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 101 clinical trials targeting Integrin alpha4beta7.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities